Log in

NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

$9.54
+0.27 (+2.91 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$8.80
Now: $9.54
$9.81
50-Day Range
$6.45
MA: $10.80
$12.60
52-Week Range
$6.35
Now: $9.54
$21.42
Volume410,587 shs
Average Volume398,196 shs
Market Capitalization$433.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.
Read More
Kura Oncology logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.83 per share

Profitability

Net Income$-63,140,000.00

Miscellaneous

Employees43
Market Cap$433.40 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have decreased by 1.1% and is now trading at $9.54. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kura Oncology.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) issued its earnings results on Tuesday, February, 25th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.03. View Kura Oncology's earnings history.

What price target have analysts set for KURA?

7 Wall Street analysts have issued 12-month price objectives for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's share price to reach $27.29 in the next year. This suggests a possible upside of 186.0% from the stock's current price. View analysts' price targets for Kura Oncology.

Has Kura Oncology been receiving favorable news coverage?

News stories about KURA stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kura Oncology earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutKura Oncology.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest during the month of February. As of February 14th, there was short interest totaling 2,700,000 shares, an increase of 6.7% from the January 30th total of 2,530,000 shares. Based on an average daily trading volume, of 282,000 shares, the days-to-cover ratio is currently 9.6 days. Approximately 6.5% of the shares of the stock are short sold. View Kura Oncology's Current Options Chain.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (15.00%), EcoR1 Capital LLC (9.36%), Victory Capital Management Inc. (5.26%), Victory Capital Management Inc. (5.24%), Eagle Asset Management Inc. (4.55%) and State Street Corp (2.34%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View institutional ownership trends for Kura Oncology.

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Driehaus Capital Management LLC, State Street Corp, Man Group plc, SG Americas Securities LLC, Nuveen Asset Management LLC, Oak Ridge Investments LLC, and UBS Group AG. View insider buying and selling activity for Kura Oncology.

Which institutional investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EcoR1 Capital LLC, Point72 Asset Management L.P., WCM Investment Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., FMR LLC, and Pathway Capital Management LP. View insider buying and selling activity for Kura Oncology.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $9.54.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $433.40 million. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 43 workers across the globe. View additional information about Kura Oncology.

What is Kura Oncology's official website?

The official website for Kura Oncology is http://www.kuraoncology.com/.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  326 (Thanks for Voting!)
Underperform Votes:  296 (Thanks for Voting!)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel